AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 261 min read$AMRZ

Sanche Jacques Wolf purchased $187K of AMRZ

Sanche Jacques Wolf purchased 4,150 shares of Amrize Ltd (AMRZ) at $45.02 ($0.19M total) on 2026-08-26.

Original reporting
SEC EDGAR · Sanche Jacques Wolf
Published Aug 26, 2026, 9:36 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 10:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AMRZ
Neutral
medium confidence
Mentioned
$AMRZ
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMRZNeutralLow
01

Why it matters

The director's purchase adds a modest amount to his holdings, indicating personal confidence but unlikely to move the stock.

02

Market read

A routine insider purchase with limited trading relevance.

03

What to watch

Potential upcoming corporate actions not disclosed yet.

Relevance 5/10Novelty 4/10Timing: same day filing

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$AMRZNeutralMedium confidence
Context

Director Sanche Jacques Wolf bought 4,150 shares at $45.02, totaling $186,833.

Expected impact

Minimal short‑term price movement expected.

Evidence & confidence

Purchase size is modest relative to float; typical for a director rebalancing holdings.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider buying could be a subtle bullish signal if the company is undervalued.

Key entities

  • Director
    Sanche Jacques Wolf

    Director of Amrize Ltd who purchased shares.

  • Company
    Amrize Ltd

    Issuer of the shares purchased.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AMRZ insider trading history →

Related articles

AUG 14
$AMRZMedAI 8/10

Amrize (AMRZ) Q2 2026 Earnings Call Transcript

Amrize AG (AMRZ) reported Q2 2026 revenue of $3.49B, up 8.6%, and net income of $476M, up 14.4%, with adjusted EBITDA of $986M. Management raised fiscal 2026 revenue guidance to $12.5B-$12.7B but revised adjusted EBITDA to $3.1B-$3.2B due to oil-driven cost inflation. The company cited data center and infrastructure demand.

fool.com6 min
AUG 10
$AMRZMedAI 8/10

Amrize Q2 EPS misses $0.94 estimate as costs weigh on margins

Amrize (NYSE: AMRZ) reported Q2 2026 adjusted EPS of $0.88, below the $0.94 consensus estimate. Revenue rose 8.51% to $3.494 billion, beating the $3.365 billion expectation. Net income increased 14.4% to $476 million. The company raised FY2026 revenue guidance to $12.5B-$12.7B but lowered adjusted EBITDA guidance to $3.1B-$3.2B due to cost inflation.

scanx.trade6 min
AUG 10
$AMRZMed

RBC Downgrades Amrize After A Rare Q2 Miss

RBC downgraded Amrize after a rare Q2 miss and reduced guidance, citing a timing mismatch between input-cost increases and the full pass-through of surcharges and price hikes. RBC cut 2026-2028 EBITDA estimates by 4%, 6%, and 7% and EPS by 12%, 14%, and 15%, lowering its stock rating to underperform and price target to $48 from $60.

finimize.com4 min